SAN JOSE, Calif., Jan. 26, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the fourth quarter of 2025 after market close on Tuesday, February 24, 2026. The Company’s management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. The Company also announced it will host an in-per ...

Company Overview - Procept BioRobotics Corporation (NASDAQ:PRCT) is a surgical robotics company focused on developing transformative solutions in urology both in the US and internationally [4]. Analyst Ratings and Price Targets - Truist analyst Richard Newitter lowered the price target on Procept BioRobotics to $47 from $50 while maintaining a Buy rating, indicating optimism about the MedTech sector despite caution regarding capital allocation [1]. - UBS analyst Danielle Antalffy initiated coverage with a Buy rating and a price target of $62, citing confidence in the company's growth potential through 2026 and 2027 based on consultations with key opinion leaders [2]. - Bank of America downgraded Procept BioRobotics to Neutral from Buy with a reduced price target of $38, down from $55, highlighting concerns over slowing utilization growth and operational challenges [3]. Market Potential and Growth Drivers - Procept's aquablation technology is noted for its significant market potential in treating benign prostatic hyperplasia, although there are concerns about the simultaneous slowdown in system sales and procedure volume [3]. - The company is focusing on initiatives to increase usage of its current hardware and exploring new system placements in untapped markets, which could drive long-term revenue growth [2]. Industry Context - The MedTech sector is viewed as potentially acting as a source of funds rather than a primary destination for new capital, with a preference for companies that have specific catalysts for growth [1].

Core Viewpoint - Procept Biorobotics Corp. (NASDAQ:PRCT) is identified as a promising mid-cap healthcare stock with significant upside potential, supported by bullish analyst ratings and growth prospects [1][3]. Group 1: Analyst Ratings and Price Targets - UBS analyst Danielle Antalffy initiated coverage with a Buy rating and a target price of $62, indicating an upside potential of over 93% from current levels [1][2]. - As of December 19, 80% of 10 analyst ratings for the stock were Buy calls, with a 1-year average price target of $51.75, suggesting over 61% upside potential [3]. Group 2: Company Overview and Growth Prospects - Procept Biorobotics Corp. specializes in surgical robotics, focusing on robotic treatments for male urological health, particularly through its flagship Aquablation® therapy [4]. - The company aims to increase the utilization of its current installed base and expand into new markets, with expectations of turning profitable by 2027 due to revenue growth, improved gross margins, and operational efficiencies [2].

Summary of PROCEPT BioRobotics FY Conference Call (December 02, 2025) Company Overview - **Company**: PROCEPT BioRobotics (NasdaqGM:PRCT) - **Industry**: Medical Technology, specifically in urology and robotic-assisted procedures Key Points and Arguments Utilization and Inventory Management - The CEO clarified that the decline in HP sales does not indicate a problem with procedure volumes but rather an inventory workdown issue [3][4] - The company is focusing on procedure volume rather than just stocking orders, which are seen as noise in the system [3][4] - Adjustments were made to guidance based on the analysis that many sites were carrying excess inventory [4] Procedure Growth - The company is pleased with the adoption of its therapy and is focusing on procedural growth [5] - The CEO emphasized the importance of efficient launches and training for new centers to drive better utilization [12][13] - A pilot program was initiated to improve the launch process, which has shown benefits [12] Patient Engagement and Market Penetration - The CEO discussed the need to educate patients about the benefits of their procedures, particularly in terms of safety and outcomes [37][38] - There is a significant opportunity to convert patients who are currently hesitant to undergo procedures due to fears of complications [25][28] Competitive Landscape - The company believes it occupies a unique position in the market, offering effective procedures with a low complication profile compared to other options [42] - The CEO highlighted the need to change the narrative around non-receptive procedures, which may initially seem attractive but lack durability [46] Capital Sales and Replacement Cycle - The capital sales team performed well despite increased scrutiny in the capital process, with a strong outlook for future placements [52][54] - The company is developing a cohesive replacement strategy for its AquaBeam systems, which is expected to become significant in 2026 [58][61] Financial Guidance - The CEO expressed confidence in the guidance provided, which reflects a status quo but also acknowledges opportunities for improvement [66][68] - Better commercial execution and the ability to replace legacy systems are seen as key drivers for achieving the high end of guidance [68] Reimbursement Landscape - Facility payments to hospitals have increased by 5% year-over-year, making the economic case for the company's procedures favorable [70] - The CEO noted that the adoption of aquablation therapy is driven more by clinical outcomes than by economic factors [71] Marketing and Education - The company plans to utilize social media and referral community education rather than large-scale advertising to promote its procedures [77] Additional Important Insights - The management team is focused on improving the training and specialization of their field staff to enhance overall performance [22][23] - The CEO's experience from previous roles is being leveraged to improve operational efficiency and patient outcomes at PROCEPT [24][25] This summary captures the essential points discussed during the conference call, highlighting the company's strategic focus on procedure growth, patient education, and operational efficiency in the medical technology sector.

Core Viewpoint - PROCEPT BioRobotics is focused on advancing patient care in urology through innovative robotic solutions, particularly in the treatment of benign prostatic hyperplasia (BPH) [3]. Company Overview - PROCEPT BioRobotics manufactures the AQUABEAM and HYDROS Robotic Systems, with the HYDROS system being the only AI-powered technology delivering Aquablation therapy [3]. - The company aims to revolutionize BPH treatment globally in partnership with urologists, emphasizing the delivery of effective, safe, and durable outcomes for men suffering from lower urinary tract symptoms (LUTS) due to BPH [3]. - BPH affects approximately 40 million men in the United States, highlighting the significant market potential for the company's solutions [3]. - The company has developed a substantial body of clinical evidence, with over 150 peer-reviewed publications supporting the benefits and clinical advantages of Aquablation therapy [3]. Upcoming Events - Management will present at the 37th Annual Piper Sandler Healthcare Conference in New York City on December 2 at 8:30 a.m. Eastern Time [1]. - A live webcast of the event will be available on the company's website, with recordings archived for at least 90 days [2].

Core Viewpoint - PROCEPT BioRobotics Corporation is recognized as a fast-growing small-cap stock, with analysts maintaining a Buy rating despite a price target reduction from $55 to $50 following strong fiscal Q3 2025 results [1][2]. Financial Performance - The company reported a revenue increase of 42.76% to $83.33 million, exceeding estimates by $2.56 million [2]. - The earnings per share (EPS) of negative $0.38 also surpassed consensus expectations by $0.04 [2]. Product and Market Demand - Revenue growth is attributed to strong demand for the HYDROS Robotic System, which saw a year-over-year growth of 43%, alongside increasing adoption of Aquablation therapy [2][3]. - PROCEPT BioRobotics develops the AQUABEAM Robotic System, a surgical robot that utilizes real-time imaging and a heat-free water jet for precise prostate tissue removal [4]. Analyst Insights - Analyst Matthew O'Brien noted that the company's Q3 performance was better than expected, with sales forecasts for 2025 and 2026 aligning closely with Wall Street's expectations [3]. - Concerns regarding soft utilization performance and investor destocking are viewed as temporary issues, attributed to internal changes within the company [3].

Financial Performance - Revenue for Q3 2025 reached $83.3 million, a 42.7% increase from $58.4 million in Q3 2024[15] - Gross profit for Q3 2025 was $54.0 million, compared to $36.9 million in Q3 2024, reflecting a gross margin improvement[15] - Net loss for Q3 2025 was $21.4 million, slightly higher than the net loss of $21.0 million in Q3 2024[15] - The company reported a comprehensive loss of $21.2 million for Q3 2025, compared to a comprehensive loss of $21.0 million in Q3 2024[15] - For the nine months ended September 30, 2025, the net loss was $65.727 million, an improvement from a net loss of $72.557 million in the same period of 2024, representing a decrease of approximately 9.4%[21] - Total revenue for the three months ended September 30, 2025, was $83.3 million, a 42.7% increase from $58.4 million in the same period of 2024[62] - Total revenue for the nine months ended September 30, 2025, reached $231.7 million, up 48.1% from $156.3 million in the prior year[62] Expenses and Costs - Research and development expenses for Q3 2025 were $18.2 million, up from $16.6 million in Q3 2024, indicating continued investment in innovation[15] - Selling, general and administrative expenses increased to $59.0 million in Q3 2025 from $42.7 million in Q3 2024, reflecting higher operational costs[15] - Total stock-based compensation recognized for the three months ended September 30, 2025, was $14.5 million, an increase from $8.5 million in the same period of 2024[50] Assets and Liabilities - Total current assets decreased to $454.8 million as of September 30, 2025, down from $481.8 million at December 31, 2024[13] - Total liabilities remained stable at $131.3 million as of September 30, 2025, compared to $131.7 million at December 31, 2024[13] - Cash and cash equivalents were $294.3 million as of September 30, 2025, down from $333.7 million at December 31, 2024[13] - The total stockholders' equity decreased to $380.3 million as of September 30, 2025, from $402.2 million at December 31, 2024[13] - Total inventory as of September 30, 2025, increased to $66.715 million from $56.168 million as of December 31, 2024, reflecting an increase of approximately 18.7%[35] - The allowance for credit losses increased to $2.266 million as of September 30, 2025, compared to $840,000 at the end of 2024, marking a significant increase of 170.5%[34] Cash Flow - Cash used in operating activities for the nine months ended September 30, 2025, was $38.658 million, compared to $66.822 million in 2024, indicating a reduction of about 42.2%[21] - The Company reported net cash provided by financing activities of $6.753 million for the nine months ended September 30, 2025, compared to $9.597 million in 2024, a decrease of approximately 29.3%[21] - The total cash and cash equivalents as of September 30, 2025, were $294.281 million, down from $333.725 million at the end of 2024, representing a decrease of about 11.8%[32] Regulatory and Compliance - The Company received FDA clearance for its next-generation HYDROS Robotic System on August 20, 2024, enhancing its product offerings in the surgical robotics market[23] - The Company plans to adopt new accounting standards related to income tax disclosures in the year ending December 31, 2025, which are not expected to have a material impact on its financial statements[28] - The company determined that new federal tax legislation enacted in July 2025 did not have a material impact on its financials due to a full valuation allowance on deferred tax assets and liabilities[63] Market and Operational Insights - U.S. revenue for the three months ended September 30, 2025, was $73.9 million, representing a 41.5% increase from $52.2 million in 2024[62] - Revenue from handpieces and other consumables in the U.S. increased by 50% to $44.4 million for the three months ended September 30, 2025, compared to $29.6 million in 2024[62] - The company operates as a single operating segment, with no customers accounting for more than 10% of revenue during the nine months ended September 30, 2025[67] - The company's assets are primarily based in the United States, with 89% of revenue coming from the U.S. for the three months ended September 30, 2025[68] Future Commitments - Future minimum annual operating lease payments total $37.6 million, with a present value of future payments at $27.4 million as of September 30, 2025[47] - The Company’s future minimum annual debt repayments total $52.0 million, with a present value of future payments at $51.6 million[44] - The Company’s minimum cash holdings requirement at CIBC stipulates that if cash and cash equivalents are less than $50.0 million, 100% must be maintained at CIBC[42] Interest Rates and Financial Metrics - The weighted-average interest rate for the Term Loan Facility was 6.7% for the period ending September 30, 2025, down from 7.7% in 2024, indicating a decrease of approximately 13%[40] - The Company had 3.7 million stock options outstanding as of September 30, 2025, with an aggregate pre-tax intrinsic value of $79.8 million[51] - As of September 30, 2025, the Company had $13.9 million of unrecognized stock-based compensation expense related to stock options[52] - Employer contributions to the defined contribution retirement savings plan were $0.7 million for the three months ended September 30, 2025, compared to $0.5 million in 2024[72] - The company's exposure to market risks related to interest rates, credit, and foreign currency exchange rates has not changed materially since December 31, 2024[117]

Group 1 - The article does not provide any relevant content regarding company or industry insights [1]

Financial Performance - PROCEPT BioRobotics Corporation reported a quarterly loss of $0.38 per share, which was better than the Zacks Consensus Estimate of a loss of $0.41, representing an earnings surprise of +7.32% [1] - The company posted revenues of $83.33 million for the quarter ended September 2025, exceeding the Zacks Consensus Estimate by 3.35% and showing a significant increase from $58.37 million in the same quarter last year [2] Stock Performance - PROCEPT BioRobotics shares have declined approximately 57.1% since the beginning of the year, contrasting with the S&P 500's gain of 16.5% [3] - The current Zacks Rank for PROCEPT BioRobotics is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6] Earnings Outlook - The consensus EPS estimate for the upcoming quarter is -$0.25 on revenues of $96.42 million, and for the current fiscal year, it is -$1.48 on revenues of $325.4 million [7] - The trend of estimate revisions for PROCEPT BioRobotics was mixed ahead of the earnings release, which could change following the recent report [6] Industry Context - The Medical - Instruments industry, to which PROCEPT BioRobotics belongs, is currently ranked in the top 38% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]

Financial Data and Key Metrics Changes - Total revenue for Q3 2025 was $83.3 million, representing a growth of 43% compared to Q3 2024 [10] - U.S. revenue for Q3 was $73.9 million, reflecting a growth of 42% year-over-year [10] - Gross margin for Q3 2025 was 64.8%, an increase of 160 basis points year-over-year [11] - Net loss for Q3 2025 was $21.4 million, compared to a loss of $21 million in the same period last year [11] - Adjusted EBITDA loss was $7.4 million, an improvement from a loss of $12.4 million in Q3 2024 [11] - Cash, cash equivalents, and restricted cash balances as of September 30 were approximately $297 million [12] Business Line Data and Key Metrics Changes - U.S. handpiece and other consumable revenue for Q3 2025 was $44.4 million, representing a growth of 50% compared to Q3 2024 [10] - Approximately 13,225 handpieces were sold in Q3, reflecting a 51% year-over-year unit growth [11] - U.S. system revenue was $24.7 million, with system revenue growth of 26% compared to Q3 2024 [11] - 57 new hydro systems were sold in Q3, with an average selling price of approximately $435,000 [11] Market Data and Key Metrics Changes - International revenue in Q3 2025 was $9.4 million, representing growth of 53% compared to the prior year period [11] - The company expects full-year international revenue to be approximately $37.5 million, representing annual growth of 56% [14] Company Strategy and Development Direction - The company aims to improve procedure utilization as a key to unlocking long-term value [5] - There is a focus on increasing therapy awareness and driving patient activation, which will be a core part of the near and midterm commercial strategy [7] - The company plans to invest in international markets that value transformational therapies [7] - Organizational changes have been made to enhance marketing and strategy capabilities [8] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ability to finish 2025 strongly despite some scrutiny in capital spending by large hospital systems [4] - The company anticipates total revenue for fiscal 2026 to be in the range of $410-$430 million, reflecting current momentum in capital sales [16] - Management acknowledged potential procedural headwinds in the first half of 2026 but remains optimistic about long-term growth [16][40] Other Important Information - The company is committed to building a world-class marketing organization to activate patients and accelerate utilization [10] - Management plans to host a formal analyst day in late February 2026 to outline multi-year revenue guidance and provide updates on various initiatives [17] Q&A Session Summary Question: Can you discuss the capital environment and the strength seen in the quarter? - Management noted strong performance in capital sales despite some variability in timing and capital allocation with customers [18][19] Question: What insights have you gained in your early tenure as CEO? - The CEO emphasized the need to better tell the company's story to clinicians and patients, highlighting the opportunity to transform medicine [21][23] Question: Can you elaborate on the utilization dynamics and expected improvements? - Management confirmed low single-digit growth in utilization but expects it to improve in Q4 due to initiatives aimed at enhancing the speed of new account launches [27][30] Question: How does the company plan to approach profitability and reinvestment? - The CEO indicated that strategic investments will be made to drive long-term growth without disrupting the path to profitability [43][44] Question: Will direct-to-consumer advertising be considered to educate patients? - Management acknowledged the need for patient education and indicated that cost-effective channels will be explored for outreach [60][63] Question: What are the expectations regarding system placements under operating leases? - Management clarified that the operating lease was a one-off situation and does not indicate a shift in business practice [74]